131020-50-3

Basic information

• Product Name: 1H-Benzimidazole-6-carboxylicacid,1-methyl-,methylester(9CI)
• Synonyms: 1H-Benzimidazole-6-carboxylicacid,1-methyl-,methylester(9CI)
• CAS NO: 131020-50-3
• Molecular Formula: C10H10N2O2
• Molecular Weight: 190.2
• Product Categories: BENZIMIDAZOLE
• Mol File: 131020-50-3.mol

Chemical Properties

• Appearance: /
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 1H-Benzimidazole-6-carboxylicacid,1-methyl-,methylester(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Benzimidazole-6-carboxylicacid,1-methyl-,methylester(9CI)(131020-50-3)
• EPA Substance Registry System: 1H-Benzimidazole-6-carboxylicacid,1-methyl-,methylester(9CI)(131020-50-3)

Safety Data

• Hazardous Substances Data: 131020-50-3(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
1H-Benzimidazole-6-carboxylic acid, 1-methyl-, methyl ester (9CI) is utilized as a key intermediate in organic synthesis, particularly for the preparation of various organic compounds and pharmaceuticals. Its unique structure and reactivity make it a valuable building block in the synthesis of complex organic molecules.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 1H-Benzimidazole-6-carboxylic acid, 1-methyl-, methyl ester (9CI) serves as a crucial component in drug discovery and development. Its potential applications in the creation of new drugs are being explored due to its versatile chemical properties and the diverse range of biological activities associated with benzimidazole derivatives.
Used in Drug Development:
As a methyl ester, 1H-Benzimidazole-6-carboxylic acid, 1-methyl-, methyl ester (9CI) may have potential applications in the development of new drugs targeting various therapeutic areas. Its chemical properties and reactivity can be leveraged to design and synthesize novel drug candidates with improved pharmacological profiles and therapeutic efficacy.

Upstream product

• 185629-31-6 methyl 3-fluoro-4-nitrobenzoate 
• 26663-77-4 methyl 1H-benzo[d]imidazole-6-carboxylate 
• 74-88-4 methyl iodide 
• 251643-13-7 methyl 3-(methylamino)-4-nitrobenzoate 
• 64-18-6 formic acid 
• 616224-38-5 methyl 4-amino-3-(methylamino)benzoate 

Downstream Products

• 53484-18-7 1-methyl-6-benzimidazole carboxylic acid 

Relevant articles and documents

Discovery of a Potent FLT3 Inhibitor (LT-850-166) with the Capacity of Overcoming a Variety of FLT3 Mutations

Secondary mutations of FLT3 have become the main mechanism of FLT3 inhibitor resistance that presents a significant clinical challenge. Herein, a series of pyrazole-3-amine derivatives were synthesized and optimized to overcome the common secondary resistance mutations of FLT3. The structure-activity relationship and molecular dynamics simulation studies illustrated that the ribose region of FLT3 could be occupied to help address the obstacle of secondary mutations. Among those derivatives, compound 67 exhibited potent and selective inhibitory activities against FLT3-ITD-positive acute myeloid leukemia (AML) cells and possessed equivalent potency against transformed BaF3 cells with a variety of secondary mutations. Besides, cellular mechanism assays demonstrated that 67 strongly inhibited phosphorylation of FLT3 and its downstream signaling factors, as well as induced cell cycle arrest and apoptosis in MV4-11 cells. In the MV4-11 xenograft models, 67 exhibited potent antitumor potency without obvious toxicity. Taken together, these results demonstrated that 67 might be a drug candidate for the treatment of FLT3-ITD-positive AML.

PRMT5 INHIBITORS AND USES THEREOF

Described herein are compounds of Formula (A), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described

Synthesis and antiprotozoal activity of nitazoxanide-N-methylbenzimidazole hybrids

A series of a novel hybrid compounds between nitazoxanide and N-methylbenzimidazole were synthesized starting from the corresponding N-methyl-2-nitroanilines. The new hybrid compounds (1-13) were evaluated in vitro against Giardia intestinalis, Entamoeba

Design, synthesis and structure-activity relationships of 1,3,4-oxadiazole derivatives as novel inhibitors of glycogen synthase kinase-3β

Glycogen synthase kinase-3β (GSK-3β) is implicated in abnormal hyperphosphorylation of tau protein and its inhibitors are expected to be a promising therapeutic agents for the treatment of Alzheimer's disease. Here we report design, synthesis and structure-activity relationships of a novel series of oxadiazole derivatives as GSK-3β inhibitors. Among these inhibitors, compound 20x showed highly selective and potent GSK-3β inhibitory activity in vitro and its binding mode was determined by obtaining the X-ray co-crystal structure of 20x and GSK-3β.

Neutrophil inhibitors to reduce inflammatory response

The invention provides novel compounds selected from the group consisting of: The compounds of the present invention are useful for the treatment and prevention of a variety of diseases and conditions associated with undesirable or abnormal inflammatory responses, such as ischemia-reperfusion injury. Accordingly, the invention further provides pharmaceutical compositions comprising these compounds. The invention still further provides methods of treatment or prevention for the above disorders using theses compounds or the compositions containing them.

4,5,6,7-tetrahydrobenzimidazole derivatives as 5HT3 -antagonists

4,5,6,7-Tetrahydrobenzimidazole derivatives represented by general formula (I) STR1 wherein groups represents the following: R1, R2, R3 : independently represent hydrogen atom, hydroxy group, a halogen atom, a lower alkyl